Join us for a KOL Event with Protalix Biotherapeutics, featuring Myrl D. Holida, PA (University of Iowa Stead Family Children’s Hospital) who will discuss the PRX-102 robust clinical program for the potential treatment of patients suffering from Fabry disease.

Members of the Protalix Biotherapeutics leadership team will provide a regulatory update regarding PRX-102, its investigational plant cell culture-expressed and chemically modified version of the recombinant alpha-Galactosidase-A protein. PRX-102 is in development for two dosing regimens with the primary goals of treating adult Fabry patients with declining renal function and potentially lowering the treatment burden of bi-weekly infusions.

A live Q&A session will follow the formal presentations.